Mesoblast shares emerged as the top performer on the ASX 200 today, fueled by strong commercial progress and positive market sentiment. The movement reflects increasing confidence in the company’s growth trajectory.
The Mesoblast share price rounded out the day up 8.06% at A$2.95, making it the leading gainer on the ASX 200. This surge reflects building momentum, with the stock now trading 85.53% higher over the past six months. Markets are closely watching whether MSB can sustain this rally and breach the A$3.00 level, a mark last achieved in February 2025.
The recent upswing is supported by several key developments. Notably, the commercial launch of Ryoncil® has shown promising early results. Back in July last year, Mesoblast reported unaudited gross revenue of US$13.2 million from the first quarter of Ryoncil sales, which commenced on March 28, 2025. Ryoncil is the first FDA-approved mesenchymal stromal cell product in the U.S. for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.
Further bolstering market confidence, Mesoblast was added to the S&P/ASX 200 Index on March 6, 2025. This inclusion has increased the company’s visibility among institutional investors and is expected to improve trading liquidity. The U.S. FDA also granted orphan-drug approval to Ryoncil in June 2025, providing seven years of market exclusivity for treating SR-aGvHD in children.
Price Targets
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Financially, Mesoblast reported a cash balance of US$145 million as of September 30. The company anticipates Q2 FY26 gross revenue to exceed US$30 million, driven by the ongoing demand for Ryoncil. This financial stability supports the advancement of late-stage programs.
Analyst forecasts project revenues of US$69.2 million for 2026, a 303% increase year-over-year. The anticipated loss per share is expected to narrow by 54% to US$0.037. The average price target remains at AU$3.49, indicating potential upside from current levels.
Bull Case:
- Strong Ryoncil launch with growing revenue.
- Inclusion in S&P/ASX 200 increases visibility.
- FDA orphan-drug approval provides market exclusivity.
Bear Case:
- Company is not yet profitable.
- Narrow pipeline focused on Ryoncil sales.
- Uncertainty in long-term revenue projections.
The positive momentum in Mesoblast’s share price reflects a combination of strong operational performance, regulatory tailwinds, and favourable market sentiment, but the company must demonstrate continued execution to justify current valuations.
